Multi-Country, Cross-Sectional Study to Characterize Real-World Burden of Disease in Adolescent and Adult Patients with Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

Multi-Country, Cross-Sectional Study to Characterize Real-World Burden of Disease in Adolescent and Adult Patients with Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa - MEASURE AAVitHS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037867

Enrollment

2795

Registered

2025-10-13

Start date

2025-11-11

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L80 L73.2 L63.9

Interventions

Group 1: Participants with Alopecia areata (AA), Vitiligo (Vit) or Hidradenitis suppurativa (HS) Collect burden of disease in one single visit

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS). Participants Ability to understand study questionnaires, with caregiver support as required for adolescents

Exclusion criteria

Exclusion criteria: Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study). Unable or unwilling to comply with study requirements and PRO collection

Design outcomes

Primary

Measure	Time frame
Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only. Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only. Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only. Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only. Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only. Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only in one single visit.	—

Measure

Time frame

Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only. Measuring scalp hair loss, assessed by the Severity of Alopecia Tool (SALT) score. AA only. Measuring facial skin depigmentation, assessed by the Facial Vitiligo Area Scoring Index (F-VASI) Vitiligo Only. Vitiligo Quality of Life (QOL), assessed by Vitiligo Quality of Life Score (VitiQoL) Vitiligo Only. Hidradenitis Suppurativa (HS) Quality of Life (QOL), assessed by Dermatology Life Quality Index (DLQI)/Children's Dermatology Life Quality Index (CDLQI) HS only. Measuring disease severity, assessed by the International Hidradenitis Suppurativa Severity Scoring System (IHS4) HS only in one single visit.

—

Secondary

Measure	Time frame
Diverse	—

Countries

Argentina, Brazil, Canada, Czechia, Estonia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Kuwait, Latvia, Lithuania, Mexico, Poland, Portugal, Puerto Rico, Qatar, Romania, Saudi Arabia, Slovakia, South Korea, Spain, Switzerland, Taiwan, United Arab Emirates, United Kingdom

Contacts

Public ContactMedical Information Germany

AbbVie Deutschland GmbH & Co. KG

medinfo.germany@abbvie.com+49 611 1720 1520

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026